Has Henry Fung, MD received payments from drug or device companies?

Yes. Drug and device makers reported $729,706 in general payments to Henry Fung, MD across 571 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Henry Fung, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Henry Fung, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Henry Fung, MD

Hematology & Oncology · Philadelphia, PANPI 1215997085

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $637,306 of the $729,706 with a category attached, or 87.3%. 24 manufacturers reported payments, led by Johnson & Johnson at 50.3% of the total. Among hematology & oncology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$729,706in general payments, 2019–2025

Across 571 payments — averaging $1277.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$367K
AstraZeneca$107K
Incyte Corporation$101K
Bristol Myers Squibb$36K
Takeda Pharmaceuticals U.S.A., Inc.$20K
Biolinerx USA, Inc.$19K
plus $79K from 18 others

$1,732,730in research payments, 2019–2025

Across 114 payments — averaging $15,199 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Bristol Myers Squibb$513K
Otsuka Pharmaceutical Co., Ltd.$506K
Genentech, Inc.$290K
Merck$236K
Gilead$176K
E.r. Squibb & Sons, L.L.C.$10K
plus $1K from 1 others

What the payments were for

Consulting fees$26,4504%
Speaking & faculty fees$637,30687%
Travel & lodging$50,4117%
Food & beverage$15,3232%
Education$2160%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson	270	$367,110
AstraZeneca(2 entities)	89	$107,223
Incyte Corporation	77	$101,240
Bristol Myers Squibb	26	$35,863
Takeda Pharmaceuticals U.S.A., Inc.	14	$20,104
Biolinerx USA, Inc.	10	$19,480
CTI Biopharma Corp.	8	$15,179
Gilead	14	$14,564
Amgen	18	$13,414
AbbVie	12	$10,615
Jazz Pharmaceuticals Inc.	9	$7,356
Sobi, Inc	4	$5,937
Karyopharm Therapeutics Inc.	4	$4,665
Pfizer	2	$3,000
Beigene USA, Inc.	2	$1,950
Sanofi	2	$1,009
Janssen Scientific Affairs, LLC	1	$450
Sanofi-aventis U.S. LLC	2	$216
Genentech USA, Inc.	1	$117
Gamida Cell Inc.	1	$67
Genentech, Inc.	1	$59
Daiichi Sankyo Inc.	2	$44
Astellas Pharma US Inc	1	$30
Fortovia Therapeutics, Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

DARZALEX$229,560
CARVYKTI$155,837
TECVAYLI$146,572
CALQUENCE$105,292
MONJUVI$100,610
RYBREVANT$93,847
Revlimid$21,230
Vonjo$20,956
APHEXDA$19,480
Kyprolis$13,093
ONUREG$12,600
Venclexta$10,281
Yescarta$9,173
XPOVIO$4,646
Tecartus$2,500
TALVEY$2,322
BRUKINSA$1,950
SOLIRIS$1,211
MOZOBIL$975
Inrebic$750

How this compares

$729,706 in reported general payments places this provider in the 95th percentile of 682 hematology & oncology providers in Pennsylvania.

See all hematology & oncology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$99,677

Medicare patients

215

Services billed

685

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Philadelphia

Charu AggarwalPhiladelphia$541K
Corey LangerPhiladelphia$492K
Ankur ParikhPhiladelphia$329K
Catherine LaiPhiladelphia$281K
Stephen SchusterPhiladelphia$218K
Keith PratzPhiladelphia$173K
David PorterPhiladelphia$140K
Adam BinderPhiladelphia$136K
Marcela MausPhiladelphia$111K
Pierluigi PorcuPhiladelphia$106K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →